Skip to main content
SpringerLink
Log in

Assessing Platelet Function in Clinical Trials

  • Chapter
Platelet Function

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Since the 1970s, the role of antiplatelet therapy in patients with coronary artery disease has become established. Aspirin was the first drug to be used as an antiaggregant. Although early trials of aspirin lacked adequate statistical power to detect clinical benefits, two metaanalyses by the antiplatelet trialist group established the place of aspirin in the management of coronary artery disease and provided significant insight into the lack of a documented dose-response effect (1,2). Although the administration of aspirin to suitable patients still lags behind desired targets, most surveys indicate that more than 90% of appropriate patients are treated with it at the time of hospital discharge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories in patients. BMJ 1994;308:81–106.

    Google Scholar 

  2. Antiplatelet Trialist’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.

    Article  Google Scholar 

  3. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676–1688.

    PubMed  CAS  Google Scholar 

  4. Yusuf S, The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

    Article  PubMed  CAS  Google Scholar 

  5. Furman M, Kereiakes D, Krueger L, et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790–798.

    Article  PubMed  CAS  Google Scholar 

  6. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000;102:1931–1936.

    PubMed  CAS  Google Scholar 

  7. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996;76:166–172.

    Article  PubMed  CAS  Google Scholar 

  8. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996;94:1239–1246.

    PubMed  CAS  Google Scholar 

  9. Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61–68.

    PubMed  CAS  Google Scholar 

  10. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365–372.

    PubMed  CAS  Google Scholar 

  11. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb 1992;12:1475–1487.

    PubMed  CAS  Google Scholar 

  12. Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab [in process citation]. Am Heart J 2000;139:696–703.

    Article  PubMed  CAS  Google Scholar 

  13. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001;33:587–594.

    Article  PubMed  CAS  Google Scholar 

  14. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251–256.

    PubMed  CAS  Google Scholar 

  15. Kleiman N, Klem J, Fernandes L, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002;143:585–593.

    Article  PubMed  CAS  Google Scholar 

  16. Hollopeter G, Jantzen H-M, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202–206.

    Article  PubMed  CAS  Google Scholar 

  17. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281–2285.

    PubMed  CAS  Google Scholar 

  18. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–2913.

    Article  PubMed  Google Scholar 

  19. Marguerie GA, Thomas-Maison N, Larrieu MJ, Plow EF. The interaction of fibrinogen with human platelets in a plasma milieu. Blood 1982;59:91–95.

    PubMed  CAS  Google Scholar 

  20. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979;254:5357–5363.

    PubMed  CAS  Google Scholar 

  21. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325–338.

    PubMed  CAS  Google Scholar 

  22. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77:670–677.

    PubMed  CAS  Google Scholar 

  23. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757–1764.

    PubMed  CAS  Google Scholar 

  24. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994;89:596–603.

    PubMed  CAS  Google Scholar 

  25. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381–389.

    Article  PubMed  CAS  Google Scholar 

  26. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101–108.

    Article  PubMed  CAS  Google Scholar 

  27. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956–961.

    Article  Google Scholar 

  28. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689–1696.

    Article  Google Scholar 

  29. The EPISTENT Study Group. randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87–92.

    Article  Google Scholar 

  30. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620–625.

    PubMed  CAS  Google Scholar 

  31. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572–2578.

    PubMed  CAS  Google Scholar 

  32. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680–1688.

    PubMed  CAS  Google Scholar 

  33. Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001;297:496–500.

    PubMed  CAS  Google Scholar 

  34. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915–1924.

    Article  PubMed  CAS  Google Scholar 

  35. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066–1073.

    PubMed  CAS  Google Scholar 

  36. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058–1065.

    PubMed  CAS  Google Scholar 

  37. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437–444.

    PubMed  CAS  Google Scholar 

  38. Mondoro TH, Wall CD, White MM, Jennings LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 1996;88:3824–3830.

    PubMed  CAS  Google Scholar 

  39. Gilchrist IC, O’Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104:406–411.

    Article  PubMed  CAS  Google Scholar 

  40. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter Trial. Circulation 1996;94:2083–2089.

    PubMed  CAS  Google Scholar 

  41. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91:2151–2157.

    PubMed  CAS  Google Scholar 

  42. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222–1227.

    Article  PubMed  CAS  Google Scholar 

  43. The IMPACT-2 Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention—IMPACT-II. Lancet 1997;349:1422–1428.

    Article  Google Scholar 

  44. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488–1494.

    PubMed  CAS  Google Scholar 

  45. Tardiff BE, Jennings LK, Harrington RA, et al. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from pursuit. Circulation 2001;104:399–405.

    Article  PubMed  CAS  Google Scholar 

  46. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with cute coronary syndromes. N Engl J Med 1998;339:436–443.

    Article  Google Scholar 

  47. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45–54.

    Article  PubMed  CAS  Google Scholar 

  48. Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 1997;28:1789–1796.

    PubMed  CAS  Google Scholar 

  49. Theroux P, White H, David D, et al. A heparin-controlled study of MK-383 in unstable angina. Circulation 1994;90:I–231.

    Google Scholar 

  50. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein Iib/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117–1121.

    PubMed  CAS  Google Scholar 

  51. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445–1453.

    Google Scholar 

  52. The PRISM PLUS Study Group. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488–1497.

    Article  Google Scholar 

  53. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888–1894.

    Article  PubMed  CAS  Google Scholar 

  54. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391–395.

    Article  PubMed  CAS  Google Scholar 

  55. Herrmann HC, Swierkosz TA, Kapoor S, et al. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002;89:1293–1297.

    Article  PubMed  CAS  Google Scholar 

  56. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial. Circulation 2002;106:1470–1476.

    Article  PubMed  CAS  Google Scholar 

  57. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536–542.

    Article  PubMed  CAS  Google Scholar 

  58. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421–1423.

    Article  PubMed  Google Scholar 

  59. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003;91:334–336.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Methodist DeBakey Heart Center, Department of Medicine, Baylor College of Medicine, Houston, TX

    Neal Kleiman MD (Director Cardiac Catheterization Laboratory)

Authors
  1. Neal Kleiman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, St. Vincent’s University Hospital, Dublin, Ireland

    Martin Quinn MB BCh BAO, PhD

  2. University College Dublin, Dublin, Ireland

    Desmond Fitzgerald MD, FRCPI, FESC, AAP (Vice President of Research) (Vice President of Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Kleiman, N. (2005). Assessing Platelet Function in Clinical Trials. In: Quinn, M., Fitzgerald, D. (eds) Platelet Function. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59259-917-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-917-2_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-244-5

  • Online ISBN: 978-1-59259-917-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation